OVERVIEW

Community Practice Connections™: Optimizing Pathologic Assessment in Lung Cancer: A Focus on Patients With EGFR Mutations is organized by Physicians' Education Resource, LLC (PER).

Release Date: November 6, 2019
Expiration Date: November 6, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
This activity features the Community Practice Connections™ platform, consisting of video clips featuring interviews with pathologists and oncologists who specialize in the diagnosis and treatment of patients with lung cancer, with a focus on lung disease expressing EGFR mutations. This online educational activity addresses topics such as current and best practices for pathologic assessment, identification of important mutations that help to direct management decisions, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapies available for various clinical scenarios, and other pertinent considerations in lung cancer.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Evaluate the utility of liquid biopsy and tumor biopsy as a pathologic approach to inform the choice of initial and later-line therapies for advanced EGFR mutation–positive non–small cell lung cancer (NSCLC)
• Assess clinical data in the management of advanced NSCLC among patients with EGFR mutations
• Relate appropriate management strategies for acquired resistance and communicate pathologic diagnostic information to the care team to optimize patient care
• Define appropriate strategies for the management of patients with advanced NSCLC and EGFR mutations in the setting of brain metastases and to proactively plan to care for treatment-related adverse events